Study of Desvenlafaxine in Treating Major Depressive Disorder.
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate if the effectiveness of desvenlafaxine
succinate sustained-release tablet (50 mg/day) used for 8 weeks is not inferior to duloxetine
hydrochloride enteric-coated capsule (60 mg/day) in adult patients with major depressive
disorder.